Organogenesis Holdings (ORGO) said late Monday the independent data monitoring committee for its second phase 3 trial of ReNu to manage symptoms related to knee osteoarthritis recommended that the study proceed without modification and without increase to the sample size.
The committee also found the safety data to be consistent with the known safety profile for ReNu, the company said.
The 594-patient trial involves the ReNu amniotic suspension allograft to treat moderate to severe symptomatic knee osteoarthritis, a degenerative joint disease
The company's shares were up more than 5% in after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。